MCRB
vs
S&P 500
MCRB
S&P 500
Over the past 12 months, MCRB has underperformed S&P 500, delivering a return of -38% compared to the S&P 500's +15% growth.
Stocks Performance
MCRB vs S&P 500
Performance Gap
MCRB vs S&P 500
Performance By Year
MCRB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Seres Therapeutics Inc
Glance View
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).
